Suppr超能文献

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.

作者信息

Schulze-Koops Hendrik

机构信息

Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University of Munich, Munich, Germany.

出版信息

Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv1-iv3. doi: 10.1093/rheumatology/kex275.

Abstract
摘要

相似文献

1
Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv1-iv3. doi: 10.1093/rheumatology/kex275.
2
Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
Reumatol Clin (Engl Ed). 2018 May-Jun;14(3):127-136. doi: 10.1016/j.reuma.2017.07.002. Epub 2017 Aug 12.
3
Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Clin Exp Rheumatol. 2016 Jul-Aug;34(4):698-705. Epub 2016 Jul 4.
4
[Biosimilars].
Z Rheumatol. 2015 Oct;74(8):670-1. doi: 10.1007/s00393-014-1490-0.
6
An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
Nat Rev Rheumatol. 2017 Feb;13(2):123-128. doi: 10.1038/nrrheum.2016.204. Epub 2017 Jan 5.
7
[Biosimilars in rheumatology. Development and results of clinical trials].
Z Rheumatol. 2015 Oct;74(8):682-8. doi: 10.1007/s00393-014-1487-8.
8
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
Joint Bone Spine. 2018 Jul;85(4):399-402. doi: 10.1016/j.jbspin.2018.03.002. Epub 2018 Mar 21.
9
Biosimilars in childhood chronic rheumatic diseases: friend or foe?
Lancet Rheumatol. 2024 Jul;6(7):e413-e414. doi: 10.1016/S2665-9913(24)00127-9. Epub 2024 Jun 3.
10
A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Expert Rev Clin Immunol. 2015;11 Suppl 1:S1-4. doi: 10.1586/1744666X.2015.1090876.

引用本文的文献

1
[Revised version of the statement by the DGRh on biosimilars-update 2017].
Z Rheumatol. 2018 Feb;77(1):81-90. doi: 10.1007/s00393-017-0407-0.

本文引用的文献

1
The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv4-iv13. doi: 10.1093/rheumatology/kex279.
2
The process defines the product: what really matters in biosimilar design and production?
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv14-iv29. doi: 10.1093/rheumatology/kex278.
3
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv30-iv48. doi: 10.1093/rheumatology/kex277.
4
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv49-iv62. doi: 10.1093/rheumatology/kex276.
6
Biosimilars for the management of rheumatoid arthritis: economic considerations.
Expert Rev Clin Immunol. 2015;11 Suppl 1:S43-52. doi: 10.1586/1744666X.2015.1090313.
7
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.
Eur J Health Econ. 2014 May;15 Suppl 1(Suppl 1):S65-71. doi: 10.1007/s10198-014-0595-3. Epub 2014 May 16.
8
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
Rheumatology (Oxford). 2013 Oct;52(10):1754-7. doi: 10.1093/rheumatology/ket187. Epub 2013 Jul 25.
9
The role of biosimilars in the treatment of rheumatic diseases.
Ann Rheum Dis. 2013 Mar;72(3):322-8. doi: 10.1136/annrheumdis-2012-202715. Epub 2012 Dec 19.
10
Update on biologic therapies in ankylosing spondylitis: a literature review.
Int J Rheum Dis. 2012 Oct;15(5):445-54. doi: 10.1111/j.1756-185X.2012.01765.x. Epub 2012 Jul 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验